|
Generic, brand name | Type | Mechanism | Clinical Dose Range (route) | Approved Tumors | Company |
|
Gefitinib, IressaZD1839 | Small molecule TKI | Inhibits intracellular EGFR tyrosine kinase phosphorylation | 250 mg daily (oral) | Platinum and taxane resistant nonsmall cell lung cancer | Astra-Zeneca |
|
Erlotinib, TarcevaOS-774CP-358774 | Small molecule TKI | Inhibits intracellular EGFR tyrosine kinase phosphorylation | 100 mg–150 mg daily (oral) | Nonsmall cell lung cancer, pancreatic cancer | OSI Pharmaceuticals/Genentech |
|
Lapatinib, TYKERBGW 572016 | Small molecule dual TKI, EGFR-1 and EGFR-2, | Inhibits heterodimerization and her1/her2 phosphorylation | 1250 mg daily days 1–21 (oral) | Her2breast cancer refractory to herceptin and chemo | Glaxo-Smith Kline |
|
Cetuximab, ErbituxIMC-C225 | Human/mouse chimeric MAb | Extracellular domain binding and ligand blockade | 400 load then 250 weekly (IV) | Metastatic colorectal cancer, head, and neck | ImClone |
|
Panitumamab, VectibixABX-EGF | Humanized MAb | Extracellular domain binding and ligand blockade | 6 mg/kg every 14 days (IV) | Metastatic refractory colorectal cancer | Amgen/Abgenix |
|